Euroopa Liit - leedu - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - dantų atmetimas - imunosupresantai - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Euroopa Liit - leedu - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antinavikiniai vaistai - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Euroopa Liit - leedu - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - cukrinis diabetas - narkotikai, vartojami diabetu - cukrinis diabetas, kai reikia gydyti insuliną. insulin human winthrop rapid taip pat tinka hiperglikeminės komos ir ketoacidozės gydymui, taip pat pacientams, sergantiems cukriniu diabetu, prieš pradinį, vidinį ir pooperacinį stabilizavimą..

Euroopa Liit - leedu - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - cukrinis diabetas - narkotikai, vartojami diabetu - cukrinis diabetas, kai reikia gydyti insuliną. insuman rapid taip pat tinka hiperglikemija koma ir ketoacidozės gydymui, taip pat siekiant pasirengimo, viduje - ir pooperacinis stabilizavimo pacientams, sergantiems cukriniu diabetu.

Leedu - leedu - SMCA (Valstybinė vaistų kontrolės tarnyba)

lohmann animal health gmbh (vokietija) - liofilizatas - vienoje vakcinos dozėje yra: gyvo nusilpninto clone 13-1 padermės niukaslo ligos viruso, - ne mažiau kaip 106,0-7,2 eid50. - vištoms ir kalakutams aktyviai imunizuoti norint sumažinti niukaslo ligos klinikinius požymius ir gaištamumą.

Leedu - leedu - SMCA (Valstybinė vaistų kontrolės tarnyba)

sanofi pasteur - inaktyvuotas pasiutligės virusas wistar rabies pm/wi 38-1503-3m padermės - milteliai ir tirpiklis injekcinei suspensijai - 3,25 tv/0,5 ml; >=2,5 tv/0,5 ml - rabies, inactivated, whole virus

Leedu - leedu - SMCA (Valstybinė vaistų kontrolės tarnyba)

pharmaceutical works polpharma s.a. - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations

Leedu - leedu - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - brinzolamidas - akių lašai (suspensija) - 10 mg/ml - brinzolamide

Leedu - leedu - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - dorzolamidas - akių lašai (tirpalas) - 20 mg/ml - dorzolamide

Leedu - leedu - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - dorzolamidas/timololis - akių lašai (tirpalas) - 20 mg/5 mg/ml - timolol, combinations